Download TX ADYUVANTE CA COLON

TRATAMIENTO ADYUVANTE
CANCER COLON
LOCALMENTE
AVANZANDO
EVALUACION CANDIDATOS A TRATAMIENTO
PRINCIPIOS TERAPIA ADYUVANTE
6 MESES
4.2%
FOLFOX VS XELOX
Seven-year DFS rates were
63% and 56% in the XELOX
and FU/FA groups, respectively
(hazard ratio [HR], 0.80; 95%
CI, 0.69 to 0.93; P = .004).
Seven-year OS rates were 73%
and 67% in the XELOX and
FU/FA groups, respectively (HR,
0.83; 95% CI, 0.70 to 0.99; P =
.04).
OS at 10 years for
N1 EC III tumors was
65.4% (95% CI,
62.8% to 68%) in the
LV5FU2 arm and was
71.4% (95% CI,
69.1% to 73.7%) in
the FOLFOX4 arm
(HR, 0.86; 95% CI,
0.67 to 1.11; P .248
for N2 EC III tumors,
OS at 10 years was
46.6% (95% CI, 43.2%
to 50%) in the LV5FU2
arm and was 59.5%
(95% CI, 56.1% to
62.9%) in the FOLFOX4
arm (HR, 0.70; 95% CI,
0.53 to 0.93; P .013;
BENEFICIO SG
NO SIGNIFC
TERAPIA BLANCO
CONCLUSIONES
• QT ADYUVANTE ES INDICADO PARA ECIII (N+) FOLFOX / CapeOx
Capecitabine or (inf.) FU/LV (ALGUNOS PCTES ) , FOLFOX / CapeOx
PARA pts < 70a
• La decision de qt adyuvante debe tener en cuenta el balance de
riesgo y comorbilidades.
MENSAJES PARA LA CASA